OSI-7904L + oxaliplatin

OSI-7904L + oxaliplatin is a combination chemotherapy regimen investigated primarily for advanced colorectal cancer. OSI-7904L is a liposomal formulation of a potent noncompetitive thymidylate synthase inhibitor (TSI), which blocks the synthesis of thymidine nucleotides required for DNA replication, thereby inhibiting tumor cell proliferation. The liposomal encapsulation enhances the drug's efficacy and half-life. Oxaliplatin is a platinum-based chemotherapeutic agent that forms DNA crosslinks, leading to apoptosis in rapidly dividing cells. The combination aims to exploit complementary mechanisms—thymidylate synthase inhibition and DNA crosslinking—to enhance antitumor activity in refractory or recurrent advanced colorectal cancer[1][2][5]. Clinical studies have focused on determining safety, tolerability, pharmacokinetics, and maximum tolerated dose of this regimen[1][2].